| 1. |
- Baiocchi, Gian Luca, et al.
(författare)
-
International consensus on a complications list after gastrectomy for cancer
- 2019
-
Ingår i: Gastric Cancer. - : Springer Science and Business Media LLC. - 1436-3291 .- 1436-3305. ; 22:1, s. 172-189
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Perioperative complications can affect outcomes after gastrectomy for cancer, with high mortality and morbidity rates ranging between 10 and 40%. The absence of a standardized system for recording complications generates wide variation in evaluating their impacts on outcomes and hinders proposals of quality-improvement projects. The aim of this study was to provide a list of defined gastrectomy complications approved through international consensus. Methods: The Gastrectomy Complications Consensus Group consists of 34 European gastric cancer experts who are members of the International Gastric Cancer Association. A group meeting established the work plan for study implementation through Delphi surveys. A consensus was reached regarding a set of standardized methods to define gastrectomy complications. Results: A standardized list of 27 defined complications (grouped into 3 intraoperative, 14 postoperative general, and 10 postoperative surgical complications) was created to provide a simple but accurate template for recording individual gastrectomy complications. A consensus was reached for both the list of complications that should be considered major adverse events after gastrectomy for cancer and their specific definitions. The study group also agreed that an assessment of each surgical case should be completed at patient discharge and 90 days postoperatively using a Complication Recording Sheet. Conclusion: The list of defined complications (soon to be validated in an international multicenter study) and the ongoing development of an electronic datasheet app to record them provide the basic infrastructure to reach the ultimate goals of standardized international data collection, establishment of benchmark results, and fostering of quality-improvement projects.
|
|
| 2. |
- Hess, Timo, et al.
(författare)
-
Dissecting the genetic heterogeneity of gastric cancer
- 2023
-
Ingår i: EBioMedicine. - : Elsevier. - 2352-3964. ; 92
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture.Methods: We did a meta-analysis of ten European genome-wide association studies (GWAS) of GC and its subtypes. All patients had a histopathologically confirmed diagnosis of gastric adenocarcinoma. For the identification of risk genes among GWAS loci we did a transcriptome-wide association study (TWAS) and expression quantitative trait locus (eQTL) study from gastric corpus and antrum mucosa. To test whether cardia GC and OAC/BO share genetic aetiology we also used a European GWAS sample with OAC/BO.Findings: Our GWAS consisting of 5816 patients and 10,999 controls highlights the genetic heterogeneity of GC according to its subtypes. We newly identified two and replicated five GC risk loci, all of them with subtype-specific association. The gastric transcriptome data consisting of 361 corpus and 342 antrum mucosa samples revealed that an upregulated expression of MUC1, ANKRD50, PTGER4, and PSCA are plausible GC-pathomechanisms at four GWAS loci. At another risk locus, we found that the blood-group 0 exerts protective effects for non-cardia and diffuse GC, while blood-group A increases risk for both GC subtypes. Furthermore, our GWAS on cardia GC and OAC/BO (10,279 patients, 16,527 controls) showed that both cancer entities share genetic aetiology at the polygenic level and identified two new risk loci on the single-marker level.Interpretation: Our findings show that the pathophysiology of GC is genetically heterogenous according to location and histopathology. Moreover, our findings point to common molecular mechanisms underlying cardia GC and OAC/BO.
|
|
| 3. |
- Jestin Hannan, Christine
(författare)
-
Esophageal and Gastroesophageal Junctional Cancer : Improving Patient selection, Treatment and Care
- 2023
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Esophageal cancer is the sixth most common cause of cancer-related death. Choice of surgical approach and individualized treatment is crucial. The aims of this thesis were to evaluate the introduction of minimally invasive esophagectomy (MIE) regarding oncological results and postoperative complications. To investigate radiological differences in pulmonary complications between MIE and open technique by studying computed tomography (CT). To evaluate geographical differences in intention for curative treatment and their association to survival. As well as to further explore these differences by comparing assessments of tumor stage (TNM) and treatment recommendations in anonymized cases at regional multidisciplinary cancer conferences (MCC).A comparison of 51 MIE (21 hybrid and 30 totally minimally invasive) and 65 open resections in 2007-2016, showed an increased lymph node yield in the MIE group, 18 (13–23) vs. 12 (8–16) median (IQR), p<0.001. The result was confirmed in a multivariate regression model (adjusted odds ratio 3.15 [1.11–8.98], p=0.03). Postoperative complications did not differ between the groups.When comparing CT after open esophagectomy (n=20) and MIE (n=20), no ipsilateral differences in the areas of atelectasis or pleural effusion were seen. Nor did the groups differ in the proportion of patients with clinically important atelectasis (dx: 30% vs. 25%, sin: 65% vs. 65%) or pleural effusion (dx: 15% vs. 15%, sin: 65% vs. 45%).A total of 5959 esophageal cancer patients, diagnosed 2006-2015 in Sweden, were identified from the National Register for Esophageal and Gastric Cancer (NREV). In a multivariable analysis, a higher rate of treatment with curative intent (time ratio 1.17 [1.05-1.30], p<0.001) and a higher resection rate (time ratio 1.24 [1.12-1.37], p<0.001) were associated with improved survival.Fifty anonymized esophageal cancer cases were distributed to five expert MCCs. In estimations of T-stage, the MCCs were in total agreement in eight of 50 cases (16%). For N-stage, total agreement was seen in 17 cases (34%) and for clinical M-stage in 34 cases (68%). The MCCs agreed on recommended treatment in 26/50 cases (52%). In conclusion, the introduction of MIE resulted in a larger lymph node yield, without increased risk for complications. No difference in postoperative pleural effusion and atelectasis was seen on computed tomography five days after open esophagectomy compared with MIE. Patients diagnosed in a county with a higher curative intention rate and a higher rate of surgery had better five-year survival and there are differences in assessment of esophageal cancer patients at different MCCs.
|
|
| 4. |
- Nilsson, Magnus, et al.
(författare)
-
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed : The Study Protocol for the Randomized Controlled NEEDS Trial
- 2022
-
Ingår i: Frontiers in Oncology. - : Frontiers Media S.A.. - 2234-943X. ; 12
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The globally dominant treatment with curative intent for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy (nCRT) with subsequent esophagectomy. This multimodal treatment leads to around 60% overall 5-year survival, yet with impaired post-surgical quality of life. Observational studies indicate that curatively intended chemoradiotherapy, so-called definitive chemoradiotherapy (dCRT) followed by surveillance of the primary tumor site and regional lymph node stations and surgery only when needed to ensure local tumor control, may lead to similar survival as nCRT with surgery, but with considerably less impairment of quality of life. This trial aims to demonstrate that dCRT, with selectively performed salvage esophagectomy only when needed to achieve locoregional tumor control, is non-inferior regarding overall survival, and superior regarding health-related quality of life (HRQOL), compared to nCRT followed by mandatory surgery, in patients with operable, locally advanced ESCC.Methods: This is a pragmatic open-label, randomized controlled phase III, multicenter trial with non-inferiority design with regard to the primary endpoint overall survival and a superiority hypothesis for the experimental intervention dCRT with regard to the main secondary endpoint global HRQOL one year after randomization. The control intervention is nCRT followed by preplanned surgery and the experimental intervention is dCRT followed by surveillance and salvage esophagectomy only when needed to secure local tumor control. A target sample size of 1200 randomized patients is planned in order to reach 462 events (deaths) during follow-up.
|
|
